Sunday , January 17 2021

A small capsule, a string and a 2 centimeter sponge have the future of screening for fatal disease – ScienceDelhi

Esophagus cancer claims more than 400,000 people worldwide. Without an effective, reliable method of screening for the disease, when the symptoms become clear, it is often too late to save the patient.

Johns Hopkins researcher who published a paper in the journal today for his career in the discovery and prevention of asaphical cancer. Clinical Cancer Research It says that it can eventually lead to easy and cheap screening for fatal disease.

In this article, a team of gastroenterologist Stefan Meltzer, researcher, clinicians and biomedical engineers, Jones Hopkins University School of Medicine, describes a test of drug and oncology – "Esophakap" – which uses specific genetic biomarkers. To find dangerous changes in cells that are the inside line of esophagus

Previous studies have demonstrated the ability to detect the condition of a biostrator named Bertrand's Asopagus, which causes the body to rotate in place of tissues, which make the limbs along the cells form a line that can lead to cancer.

But as a screening tool, the large scale methods for deploying biomarkers have remained elusive until now.

The principle behind the Elphocap is simple, says the Meltzer. The patient swallows a small capsule, which has a long string with it. The capsule goes down into the esophagus and stomach – a process that takes only a minute – begins to melt the gelatin coat on the capsule.

It capsule 2 centimeters of polypropylene sponge, which is still attached to the string, from which it still hangs from the mouth of the patient.

The screener gently pulls the string and the sponge starts out from its back, from the abdomen, into esophagus and finally, the patient's mouth.

As it moves its way, sponges come in contact with the full length and width of esophagees, which collect all the genetic material. Then, as the sponge approaches the top, the screener gives a final soft tone, which popping the rear sponge of the upper spindle muscles of the limb. Sponge is a genetic material filled with the key of the patient's asphyxial health.

Then the sponge is sent to a company that performs simple genetic tests to determine the patient's risk of aspirical cancer on the massage.

"Early detection is the perfect bolt when it comes to elphofalic cancer," says Melator. "Patients have a great opportunity to treat it – or even stop it – if they know their risks, we think this little sponge can bring people from all over the world a simple and inexpensive screening."

With approximately half a million new cases in a year, asophageal cancer is the eighth most common cancer worldwide, with the highest rates in parts of Africa and Asia.

In 2016, the United States had diagnosed about 17,000 new cases, and about 16,000 people died from isofagus cancer. In recent years, the number has increased sharply.

The five year survival rate for people with cancer has been limited to 43 percent of the Asofagas. When it spreads to nearby tissues or organs, it reaches every 23 percent. And asophageal cancer that is spreading in parts of the body, it gives a 5-year percentage rate of only 5%.

In previous researches, Meltzer has done a hard test on the set of genetic biomarkers used to diagnose barrett's esophagus. Gene compound of page 16, NELL1, AKAP12 and TAC1 achieves approximately 92% sensitivity and offers a reliable diagnosis.

There is never a regular screening of medicine for this disease. Both endoscopy and biopsy are less than ideal, because it is inappropriate, expensive and depends on random tissue samples rather than material from the full isofagus lining.

According to Meltzer, "It is really possible to miss early cancer cells by using endoscopy with biopsy and most patients of the barrettes do not pass endoscopy." "Right now, we are confident that we have the tools to identify these types of cancer, but there was no way to collect enough genetic material to determine the first diagnosis of the patient. We believe that asaphcap now provides solutions to this serious problem."

During the study of Mellzer, 94 people gave this EsophaCap test. With 100 percent successful sponge recovery, 25 percent of people were able to swallow capsules. Endoscopic evaluation of patients after the asaphac administration, Maltzar reported that there is no evidence of bleeding, pain, shock or other adverse reactions to the test.

In the journal article, Meltzer reported that half of the patients capable of swallowing capsules will be diagnosed with barrettic esophagus – which is common in the U.S. There is a lot more than population. He noted that most of the patients registered in the study have been treated for gastrointestinal symptoms. "He can explain why we showed Barrett's esophage rates more than the general public," he says.

Additional authors of the study, Xixionang Wang, PhD; Swatha Kumbhapati, M. D.; Yulan Cheng, M. D.; K. Ma, MD .; Seam Simsack, M. D.; Alan H. Tiu, M. D.; John M. Abraham, PhD; Xi Liu, PhD; Vishnu Pathas, M. D.; Mark Duncan, M. D.; Alexandra Stark, b. S.; Alexander Trick, b. S.; Hua Ling Ling, PhD; Hao Wang, Ph.D .; Yolong Hey, PhD; Mounen A. Khashab, M. D.; Sawney Ngamruengfong, MD .; Yun G Shin, M. D. And Taza-Hui Wang, PhD.

This work was supported by National Health Organizations (grant CA211457 and DK118250), the Emerson Cancer Research Fund and the Discovery Award from the Jones Hopkins University School of Medicine. Stephen Meltzer Harry and Betty Myburgh-Thomas R. Hendricks is a professor and professor of clinical research at the American Cancer Society. Xixiong Wang was supported by 3-3 funds from Scholarships from China Scholarships Council (CSC) and Sun Yat-Sen University's first affiliated hospital.

Source link